Audit Biologic Suppliers for FDA Section 361 Compliance

Auditing biologic suppliers for FDA Section 361 compliance requires verifying active 21 CFR 1271 establishment registration, certified donor eligibility records, minimal manipulation processing protocols, and documented homologous use intended for tissue repair. Reviewing lot-specific Certificates of Analysis and Current Good Tissue Practice (cGTP) controls before purchasing protects your practice from regulatory enforcement actions and product liability. Learn the step-by-step audit workflow to vet your biologics vendors with confidence.

Understanding the FDA Regulatory Framework for Biologics

The U.S. Food and Drug Administration (FDA) regulates human cells, tissues, and tissue-based products under Title 21 of the Code of Federal Regulations (CFR), Part 1271. Within this framework, HCT/Ps are categorized into two primary regulatory pathways: Section 361 and Section 351 of the Public Health Service (PHS) Act.

Section 361 products are regulated solely to prevent the introduction, transmission, or spread of communicable diseases. They do not require pre-market approval or FDA licensure if they meet four specific criteria defined in 21 CFR 1271.10(a):

1. Minimal Manipulation: Processing does not alter the relevant biological characteristics of tissue for structural products, or the relevant cellular characteristics for non-structural products.
2. Homologous Use: The tissue performs the same basic function or functions in the recipient as in the donor.
3. No Combination: The product is not combined with another article, such as drugs, devices, or synthetic materials, except for approved water, crystalloids, or sterilizing agents.
4. Systemic Effect / Metabolic Reliance: The product does not depend on the metabolic activity of living cells for its primary function, OR if it does, it is intended for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use.

If a product fails to meet any one of these criteria, it is classified as a Section 351 biologic, requiring an Investigational New Drug (IND) application and an approved Biologics License Application (BLA). Practice managers evaluating biologics must establish clear internal audit protocols to ensure all tissue products purchased fall cleanly within regulatory boundaries.

Checklist: How to Audit Biologic Suppliers for FDA Section 361 Compliance

When evaluating a prospective or existing tissue supplier, practice administrators and clinical directors should execute a standard operating procedure (SOP) that reviews five critical compliance domains.

1. Verification of FDA Establishment Registration (Form FDA 3356)

• Request a copy of the supplier’s and processor’s current FDA Establishment Registration (FEI number).
• Verify the listing status on the public FDA eLIST database to confirm that registration is active and renewed annually.
• Confirm whether the supplier acts as a manufacturer, processor, packager, or distributor.

2. Processing and Minimal Manipulation Verification

• Review technical white papers and processing flowcharts to confirm no chemical cross-linking, enzymatic digestion, or structural alteration occurs during manufacturing.
• Confirm that structural tissues (such as amnion, cord tissue, or dermal matrices) retain their primary physical structural integrity.
• Require supplier certification that cellular viability claims do not violate 361 criteria regarding systemic metabolic function.

3. Donor Screening and Communicable Disease Testing Protocols

• Confirm strict compliance with 21 CFR 1271 Subpart C (Donor Eligibility).
• Verify that donor screening includes medical history evaluation, behavioral risk assessment, and clinical records review.
• Validate that testing is performed by a CLIA-certified laboratory using FDA-cleared donor screening test kits for HIV-1/2, Hepatitis B (HBsAg and Anti-HBc), Hepatitis C (Anti-HCV and HCV NAT), Syphilis, and HTLV-I/II.

4. Quality Systems and cGTP Audits

• Verify that manufacturing facilities operate under Current Good Tissue Practice (cGTP) as outlined in 21 CFR 1271 Subpart D.
• Request summary documentation of environmental monitoring, cleanroom certifications (ISO class standards), and microbial safety testing.
• Confirm existence of terminal sterilization validation or aseptic processing validation procedures.

5. Chain of Custody, Storage, and Lot Traceability

• Confirm that every shipment includes a lot-specific Certificate of Analysis (CoA) and Certificate of Conformance (CoC).
• Ensure shipping protocols include validated temperature-controlled containers with continuous temperature data loggers.
• Audit the supplier's recall procedure and tracking system to confirm tissue can be traced from donor to recipient within 24 hours of notification.

Clinical Leadership Focus: Evaluating Homologous Use and Product Safety

For medical directors and treating physicians, auditing a biologic vendor goes beyond regulatory paperwork—it directly impacts patient outcomes and clinical integrity. Clinicians evaluating tissue products must scrutinize the supplier’s marketing materials and educational documentation.

If a supplier advertises an allogeneic tissue for non-homologous applications (for example, marketing structural amniotic tissue for systemic autoimmune conditions or metabolic repair), the product risks reclassification by the FDA as an unapproved drug. Practicing under an unapproved Section 351 classification exposes clinicians to professional board scrutiny and liability risks.

Clinical leaders should review product inserts to verify that intended use descriptions match accepted clinical literature. Providers specializing in pain management or musculoskeletal care must ensure that all tissue matrices are utilized strictly for structural repair, replacement, or cushioning of homologous tissues.

Practice Management Focus: Risk Mitigation and Inventory Logistics

For practice managers and administrative officers, vendor compliance directly affects overhead, operational continuity, and risk exposure. Integrating non-compliant tissue products into a clinical practice introduces financial risks, including potential product seizures, third-party audit clawbacks, and legal challenges.

Practice administrators should enforce strict procurement guidelines:

• Document Retention: Maintain a centralized compliance binder (digital or physical) containing FDA 3356 forms, CoAs, and donor eligibility statements for every lot purchased. Records must be retained for at least 10 years after administration or expiration, per regulatory guidelines.
• Receiving Logs: Designate trained personnel to inspect incoming shipments for seal integrity, temperature indicator status, and packaging damage before accepting inventory.
• Vendor Standardization: Limit biologic procurement to vetted distributors who provide transparent regulatory documentation and consistent quality assurances. You can learn more about regulatory standard operating procedures in our publications library.

What This Means for Your Practice

To ensure your facility remains fully compliant with FDA regulations while delivering high-quality tissue products, implement the following immediate action steps:

1. Conduct a Vendor Documentation Audit: Request updated FDA registration forms, cGTP compliance summaries, and master product descriptions from all current tissue vendors.
2. Review Labeling and Intended Use: Audit internal consent forms and patient materials to ensure claims reflect homologous use standards.
3. Formalize Receiving Protocols: Train clinical staff on log-in procedures, lot tracking, and quarantine protocols for compromised shipments.
4. Establish Vendor Review Schedules: Schedule annual compliance reviews for all third-party biologic manufacturers and distributors.

Partnering with Compliant Biologic Vendors

Navigating regulatory requirements for allogeneic tissues requires reliable supply partners dedicated to transparency, quality systems, and legal compliance. Working with experienced distributors ensures your practice receives thoroughly vetted products supported by complete regulatory documentation.

For questions regarding product compliance, quality documentation, or integrating compliant tissue products into your workflow, contact the team at Dallas Regenerative Solutions to speak with a specialist.